IP Library Granted Patent US 9,562,018
Granted Patent B2
US 9,562,018 · App. 14/655,642 · Granted Feb 7, 2017

Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Inventors: Stéphane Burlet (Croix, FR); Cécilia Estrella (Lomme, FR); Mathieu Barrier (Wavrin, FR); Patricia Melnyk (Annoeullin, FR); Nicolas Sergeant (Ronchin, FR); Luc Buee (Templemars, FR); Philippe Verwaerde (Santes, FR)
Assignee: Alzprotect
C07D235/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,562,018
App. No.
14/655,642
Granted
Feb 7, 2017
Kind
B2
Abstract

The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.

Claims (11)

1. A sulphate salt of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof.

2. The sulphate salt of claim 1 , having Formula II

wherein x designates the number of equivalents of sulphuric acid and x is 0.5 to 4, and pharmaceutically acceptable solvates thereof.

3. The sulphate salt of claim 2 and pharmaceutically acceptable solvates thereof, wherein x is 1.5 to 2.5.

4. The sulphate salt of claim 2 and pharmaceutically acceptable solvates thereof, wherein x is 0.5 to 1.5.

5. The sulphate salt of claim 2 and pharmaceutically acceptable solvates thereof, wherein x is 2.5 to 3.5.

6. The sulphate salt of claim 2 , having formula Formula III

wherein

x is as defined in claim 2 , and

y designates the number of equivalents of water and y is 0.5 to 5.

7. A medicament comprising a sulphate salt according to claim 1 , or a pharmaceutically acceptable solvate thereof.

Assignments (2)
MERGER Recorded Dec 8, 2020
From: UNIVERSITÉ DE LILLE 2 DROIT ET SANTÉ
To: UNIVERSITÉ DE LILLE
Reel/Frame 054582/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2016
From: BURLET, STÉPHANE; ESTRELLA, CÉCILIA; BARRIER, MATHIEU; MELNYK, PATRICIA; SERGEANT, NICOLAS; BUEE, LUC; VERWAERDE, PHILIPPE
To: ALZPROTECT; UNIVERSITE DE LILLE 2 DROIT ET SANTE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Reel/Frame 038196/0784 →
Priority Claims (1)
EP 12306690 · Dec 27, 2012 · regional
Continuity (1)
Related Publication 20160108003A1 · Apr 21, 2016